TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01576432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assess pain with the NIPS score
Description: In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assess pain with the NIPS score
Description: In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assess pain with the NIPS score
Description: In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.
Study: NCT00801931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Horse Antithymocyte Globulin
Description: Horse Antithymocyte Globulin (ATG \[horse\]) will be diluted in 0.9% sodium chloride or 0.45% sodium chloride for IV infusion (through an inline filter with pore size of 0.2 micrometer) to a concentration of 1-4 mg/ml and infused through a central venous catheter over 8 hours in Regimen E.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Antithymocyte Globulin
Description: Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Antithymocyte Globulin
Description: Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Antithymocyte Globulin
Description: Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit Antithymocyte Globulin
Description: Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa should be diluted in NS (1-5 mg/ml) and infused over 2 hrs on Days -8, -4. IV fluids should be at maintenance rate (1500 ml/m2).
Study: NCT00510640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Capsule, 12.5 or 50 mg, starting dose level 50 mg daily
Study: NCT02476279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement
Study: NCT02037139

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Standard care screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening
Description: Standard care screening
Study: NCT02476279

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
Study: NCT02845206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient specific cutting blocks
Description: 'MyKnee' Instrumentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cutting blocks
Description: Standard Instrumentation
Study: NCT03545503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Etomidate will be administered as the sedative for RSI on even days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be administered as the sedative for RSI on odd days
Study: NCT02856854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMB-001
Description: EMB-001 is a combination of metyrapone (720mg per dose in this study) and oxazepam (24mg per dose in this study)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: EMB-001 matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine IV
Description: Cocaine administered at doses of 20 and 40mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine IV
Description: Cocaine administered at doses of 20 and 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline IV
Description: Cocaine matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline IV
Description: Cocaine matched placebo
Study: NCT03231631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education plan and adherence to exercise
Description: * Send text messages with motivational sense at any time of the day, every 3 or 4 days.~* They will be given the option of performing directed exercise at the cardiac rehabilitation center.~* It will be recorded in an Excel table every time that text is sent to the patient.~* At the beginning and monthly, a brochure will be sent out explaining how physical activity is performed at home in case you can not walk.~* A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~* These activities will be carried out for 12 weeks. At the end of week 12, patients will be referred to the cardiac rehabilitation unit in order to perform the aerobic capacity test again.
Study: NCT01683656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: niacin/laropiprant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
Study: NCT02262624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study: NCT02037139

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Standard care screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brochure
Description: Participants are given an illustrated educational brochure
Study: NCT02262624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorthiazide (HCTZ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/HCTZ fixed combination
Study: NCT02615080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRD007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01075802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Dose escalation
Study: NCT02510209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Outreach Program
Description: TOP® is a youth development and service learning program for youth ages 12 to 17 designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP® program model consists of three components implemented in school, after school, or in community settings over nine consecutive months: (1) weekly curriculum sessions, (2) community service learning (CSL), and (3) positive adult guidance and support. The TOP® Changing Scenes® curriculum is separated into four age- and stage-appropriate levels, which range from Level 1, typically for youth ages 12 or 13, to Level 4, typically for youth age 17.
Study: NCT01096823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Description: Iyengar Yoga classes twice a week for six weeks
Study: NCT01788787

Intervention type: BEHAVIORAL
Intervention: Quitline-Delivered Proactive Telephone Counseling
Description: Smokers who enroll in treatment receive standard counseling protocol offered by the Quitline. This includes up to five proactive telephone counseling calls, each designed to provide practical expert support to help smokers develop problem-solving and coping skills, secure social support, and design a plan for successful cessation and long-term abstinence.

Intervention type: BEHAVIORAL
Intervention: Follow-Up Phone Call
Description: Six months after enrolling in treatment with the Texas Quitline, an MD Anderson research team member will contact patients to assess their smoking status via telephone.

Intervention type: BEHAVIORAL
Intervention: Smoking Cessation Training
Description: Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians) receive initial face-to-face group training on how to ask patients about their smoking status, advise them to quit, and connect them with the Quitline. The specific content of the session will include information on quitting smoking, how to implement AAC, the effectiveness of telephone counseling for smoking cessation delivered via quitlines, and pharmacotherapies including nicotine replacement.

Intervention type: BEHAVIORAL
Intervention: Qualitative Interviews Concerning the Implementation of AAC
Description: MD Anderson staff conduct individual in-depth interviews with administrative leadership as well as those medical staff who are authorized to enter patient information into the EMR and are trained in the Ask-Advise-Connect approach. All in-depth interviews will be recorded and transcribed.
Study: NCT03751046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial-Based Cognitive Therapy
Description: Participants in the TBCT intervention arm will have 14 (fourteen) psychotherapy sessions over a period of 7 (seven) months. The frequency of the intervention is biweekly with a duration of approximately 90 minutes per session. We will have10 groups with 5 participants each. All participants will practice the learned techniques during the meetings, have a manual with a description summary of the sessions and the activities to practice at home. The main TBCT techniques that will be used are case conceptualization, intrapersonal thought record, consensual role-play, action plan, trial-based thought record and trial-based metacognitive awareness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group. Standard healthcare.
Description: Participants with therapeutic failure, receiving the standard healthcare in the HIV / AIDS Program, which includes at least a half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each).~The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV
Study: NCT03281655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visnadine, prenylflavonoids and bovine colostrum
Description: 15 days, 1 application per day, with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
Study: NCT03704246

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-PD-1 monoclonal antibody
Description: HX008 is a monoclonal antibody drug which is intravenous drip at a dose of 200mg.
Study: NCT02037139

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Participants are given an illustrated educational brochure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants undergo a in-person educational intervention
Study: NCT01219309

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3/6 fatty acids
Description: 3 capsules bid orally
Study: NCT01744392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education intervention
Description: Each patient will receive instructions on how to use the medication calendar to help them adhere to their medication regimen. The Meducation Calendar is developed by the clinical pharmacist participating in the research study). The clinical pharmacist will enter the medication regimen for each participant into the application for Meducation Calendar Development.
Study: NCT01583231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prewash
Description: The intervention will be the addition of the prewash utilizing non-antimicrobial soap and water.
Study: NCT03686631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Arm
Description: The smartphone arm will have an associated smartphone application, available in kiosk mode, that will remind and encourage patient to utilize the spirometer and provide a gamified application for that patient to do so.
Study: NCT00536536

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Obesity management framework
Description: Treatment in primary care will be compared to treatment in a secondary hospital setting. Treatment in both cases will be provided by a multi-disciplinary team of: obesity or practice nurse, dietitian, exercise specialist with some input from medical team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Obesity management framework
Description: Treatment in primary care will be compared to treatment in a secondary hospital setting. Treatment in both cases will be provided by a multi-disciplinary team of: obesity or practice nurse, dietitian, exercise specialist with some input from medical team.
Study: NCT05468892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine Tipiracil
Description: Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily, with a glass of water within 1 hour after completion of morning and evening meals, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period. One treatment cycle with Trifluridine-Tipiracil consists of the following:~Days 1-5: Trifluridine / Tipiracil (35 mg/m2/dose) orally twice daily Days 6-7: Rest Days 8-12: Trifluridine / Tipiracil(35mg/m²/dose) orally twice daily Days 13-28: Rest

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine Tipiracil
Description: Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily, with a glass of water within 1 hour after completion of morning and evening meals, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period. One treatment cycle with Trifluridine-Tipiracil consists of the following:~Days 1-5: Trifluridine / Tipiracil (35 mg/m2/dose) orally twice daily Days 6-7: Rest Days 8-12: Trifluridine / Tipiracil(35mg/m²/dose) orally twice daily Days 13-28: Rest

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]
Description: Panitumumab will be administered as a 6 mg/kg intravenous infusion over 60 minutes every 2 weeks (q2w) of a 28-day cycle (Day 1 and Day 15).
Study: NCT02942524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Complete TEPID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT00577577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3
Description: 1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
Study: NCT03913780

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise more force
Description: The work force for aerobic exercise is 50 to 70% of your maximum heart rate (HRM) achieved in the stress test according to the Naughton protocol. For strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise more force
Description: The work force for aerobic exercise is 50 to 70% of your maximum heart rate (HRM) achieved in the stress test according to the Naughton protocol. For strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale.
Study: NCT01219309

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (olive oil)
Description: 3 capsules bid orally
Study: NCT00623324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aplindore
Description: Tablets .05 - 5 mg BID dosing for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match the number of active tablets
Study: NCT01329237

Intervention type: OTHER
Group type: OTHER
Intervention: dynamic physical exercise and OCT imaging
Description: supine dynamic physical exercise during coronary angiography and optical coherence tomography OCT imaging of the coronary stent
Study: NCT02241564

Intervention type: OTHER
Intervention: Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection

Intervention type: DRUG
Intervention: Switch from calcineurin inhibitor to an mTOR inhibitor
Study: NCT02256566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: emotional memory training exercise
Study: NCT03913780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise more force
Description: The work force for aerobic exercise is 50 to 70% of your maximum heart rate (HRM) achieved in the stress test according to the Naughton protocol. For strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale.
Study: NCT01556191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: 250 mg per day (oral)
Study: NCT02256566

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: memory training exercise
Study: NCT03393494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene and Benzoyl Peroxide Topical Gel
Description: Test product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo Topical Product
Description: RLD product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel
Study: NCT03115944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alma vShape Ultra
Description: UltraSpeed ultrasound treatment, a series of four treatments
Study: NCT00429949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study: NCT02316561

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single dose ablative radiotherapy
Description: A single dose ablative radiotherapy will be delivered prior to surgery
Study: NCT01556191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg per day (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150 mg per day (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg per day (oral)
Study: NCT02528526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXY111A
Description: OXY111A intravenous infusion
Study: NCT03192826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide/Brimonidine FC
Description: 1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine 0.2%
Description: 1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: 1 drop of artificial tears 1 hour before Nd-YAG capsulotomy